Last reviewed · How we verify
NCT05373459
Effect of a Third COVID-19 Booster Among Health Care Workers
trial testing Third COVID-19 booster in COVID-19 Vaccines in 3,167 participants. Completed in 31 December 2022.
31 December 2022
Quick facts
| Lead sponsor | Hong Kong Sanatorium & Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,167 |
| Start date | 16 May 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Third COVID-19 booster — full drug profile →
Conditions studied
- COVID-19 Vaccines — all drugs for COVID-19 Vaccines →
Sponsor
Hong Kong Sanatorium & Hospital — full company profile →
Who can join
18 and older, any sex, with COVID-19 Vaccines. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A new wave of COVID-19 infections, mainly caused by the Omicron/ Delta variant, has been sweeping the globe since the start of 2022. In response, the administration of a third dose of COVID-19 vaccine was considered to address potential waning immunity over time and reduced effectiveness against the Omicron/ Delta variant. The pandemic also resulted in many infections among health care workers (HCWs) and their households. In this study, a retrospective analysis would perform on risk of COVID-19 infection and their outcome in relation to their COVID-19 vaccination history by using the data repository from one of the Hong Kong private hospitals. HCWs were required to submit a standardized online self-declaration form for report of 1) demographic of the HCWs, 2) symptoms related history and 3) COVID-19 exposure history once they were COVID-19 confirmed by rapid antigen test against COVID-19 and/or polymerase chain reaction (PCR) test for COVID-19. Subsequent follow up such as contact tracing, COVID-19 PCR testing results of these HCWs and status of return to work were captured by the infection control team in a systematic manner.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05373459
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Vaccines
Currently open trials in the same condition.
- NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
- NCT05556720 — Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Contro · Phase 3 · active not recruiting
- NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting
Other Hong Kong Sanatorium & Hospital trials
Trials by the same sponsor.
- NCT07130682 — Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial · NA · recruiting
- NCT04898946 — Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong · completed
- NCT04496141 — Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19 · completed
- NCT04416061 — The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic · completed
- NCT03406325 — Mast Cell Activation Test in Allergic Disease · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05373459 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hong Kong Sanatorium & Hospital
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05373459.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing